Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.
Breaking News:
- 48 Hours, Your Way at Vida Hotels and Resorts
- LG ELECTRONICS INVITES THE WORLD TO EXPERIENCE “INNOVATION IN TUNE WITH YOU” AT IFA 2026
- LG ELECTRONICS EARNS NVIDIA AI FACTORY VALIDATION FOR ITS 600KW COOLANT DISTRIBUTION UNIT
- See Out the Summer on a High Note at Al Habtoor Polo Resort with a Line-Up of Dining, Entertainment, and Staycation Experiences
- GFH REPORTS AN INCREASE OF 13.33% IN NET PROFIT ATTRIBUTABLE TO SHAREHOLDERS FOR THE FIRST HALF OF 2026 TOTALING US$ 76.20 MILLION
- PUBG MOBILE Partners with Do Big Studios to Bring Brainrot Royale to World of Wonder
- Business Lunch at Origins – Vida Dubai Mall
- Tech Mahindra Unveils Sonic Identity, Marking the Next Phase of Its Brand Transformation
Saturday, August 15